# US 11,999,773 B2 · Anti-BCMA chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,999,773 B2
- Document ID: US11999773B2
- Status: Granted
- Kind: B2
- Application number: 17/540,947
- Filed: 2021-12-02
- Published: 2022-03-24
- Granted: 2024-06-04
- Earliest claimed: 2019-03-15
- Assignees: Cartesian Therapeutics, Inc.
- Applicants: Cartesian Therapeutics, Inc.
- Inventors: Yi Zhang; C. Andrew Stewart; Metin Kurtoglu; Murat V. Kalayoglu; Michael S. Singer
- Web page: https://patentgrep.com/patent/US11999773B2

## CPC

- C07K 14/70517: {CD8}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4215: {Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C12N 5/0636: {T lymphocytes}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 2039/505: {comprising antibodies}
- A61K 2239/46: characterised by the cancer treated
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

## Claims

### Claim 1

A protein comprising an antigen-binding portion, wherein the antigen-binding portion is an anti-B-Cell Maturation Antigen (BCMA) binding domain comprising:
a heavy chain complementarity determining region 1 (CDRH1) comprising any one of SEQ ID NOs: 1-3;
a heavy chain complementarity determining region 2 (CDRH2) comprising any one of SEQ ID NOs: 4-6;
a heavy chain complementarity determining region 3 (CDRH3) comprising any one of SEQ ID NOs: 7-9;
a light chain complementarity determining region 1 (CDRL1) comprising SEQ ID NO: 11;
a light chain complementarity determining region 2 (CDRL2) comprising any one of SEQ ID NOs: 12-15; and
a light chain complementarity determining region 3 (CDRL3) comprising any one of SEQ ID NOs: 16-18.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the CDRH1 comprises SEQ ID NO: 2.

### Claim 3 (depends on 1)

The protein of claim 1, wherein the CDRH2 comprises SEQ ID NO: 6.

### Claim 4 (depends on 1)

The protein of claim 1, wherein the CDRH3 comprises SEQ ID NO: 9.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the CDRL2 comprises SEQ ID NO: 14.

### Claim 6 (depends on 1)

The protein of claim 1, wherein the CDRL2 comprises SEQ ID NO: 15.

### Claim 7 (depends on 1)

The protein of claim 1, wherein the CDRL3 comprises SEQ ID NO: 17.

### Claim 8 (depends on 1)

The protein of claim 1, wherein the CDRH1 comprises SEQ ID NO: 2; the CDRH2 comprises SEQ ID NO: 6; the CDRH3 comprises SEQ ID NO: 9; the CDRL1 comprises SEQ ID NO: 11; the CDRL2 comprises SEQ ID NO: 14; and the CDRL3 comprises SEQ NO: 17.

### Claim 9 (depends on 1)

The protein of claim 1, wherein the CDRH1 comprises SEQ ID NO: 2; the CDRH2 comprises SEQ ID NO: 6; the CDRH3 comprises SEQ ID NO: 9; the CDRL1 comprises SEQ ID NO: 11; the CDRL2 comprises SEQ ID NO: 15; and the CDRL3 comprises SEQ NO: 17.

### Claim 10 (depends on 1)

The protein of claim 1, wherein the protein comprises a bispecific antibody.